FDA approved Benlysta (belimumab) for Pediatric and Adult Lupus NephritisFDA approved Benlysta for lupus kidney disease in children and adults

Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor. It blocks the binding of soluble BLyS to its receptors on B cells, thereby reducing the survival and differentiation of B cells, including autoreactive B cells that contribute to the pathogenesis of systemic lupus erythematosus and lupus nephritis.

Benlysta is indicated for the treatment of patients 5 years of age and older with: - Active systemic lupus erythematosus (SLE) who are receiving standard therapy. - Active lupus nephritis who are receiving standard therapy.

Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of Benlysta is not recommended in this situation.

Benlysta may be administered intravenously or subcutaneously. Vials are for intravenous use only; autoinjectors and prefilled syringes are for subcutaneous use only.

Intravenous dosage (for active SLE or lupus nephritis): - 10 mg/kg at 2-week intervals for the first 3 doses, then at 4-week intervals thereafter. - Reconstitute, dilute, and administer as an intravenous infusion over 1 hour. - Consider prophylactic premedication for infusion reactions and hypersensitivity reactions.

Subcutaneous dosage: - For adults with active SLE: 200 mg once weekly. - For pediatric patients 5 years and older (weight-based dosing, autoinjector only): - ≥40 kg: 200 mg once weekly. - 15 kg to less than 40 kg: 200 mg once every 2 weeks. - For active lupus nephritis in adults: 400 mg once weekly for 4 doses, followed by 200 mg once weekly. - For pediatric patients with active lupus nephritis (weight-based, autoinjector only): - ≥40 kg: 400 mg once weekly for 4 doses, followed by 200 mg once weekly. - 15 kg to less than 40 kg: 200 mg once weekly for 4 doses, followed by 200 mg once every 2 weeks.

Note: The prefilled syringe has not been studied in children less than 18 years of age. The 400-mg dose requires administration of two 200-mg injections.

Trial data not available in label.

Contraindications: Benlysta is contraindicated in patients with a history of anaphylaxis to belimumab or any of the excipients.

Warnings and Precautions: - Hypersensitivity reactions, including anaphylaxis, have been reported. Administer by healthcare providers prepared to manage anaphylaxis. For intravenous use, consider premedication for prophylaxis against infusion reactions and hypersensitivity reactions. - The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. The infusion must be discontinued immediately if the patient experiences a serious hypersensitivity reaction. - Efficacy has not been evaluated in patients with severe active CNS lupus; use is not recommended in this situation.

Benlysta is a biologic therapy approved for active SLE and active lupus nephritis in patients 5 years and older, used in combination with standard therapy. It provides an additional option for clinicians managing these conditions, particularly in lupus nephritis where it may be used alongside standard immunosuppressive regimens. However, its place relative to other therapies is not detailed in the label, and clinicians should consider individual patient factors and the lack of efficacy data in severe CNS lupus.